FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

American Health Packaging Recall of Valsartan

American Health Packaging recalls one lot of valsartan tablets,160 mg , due to the detection of trace amounts of an unexpected carcinogen in the finis...

Medical Devices

Zeiss Medical Technology 510(k) for Epithelial Mapping

FDA clears a Zeiss Medical Technology 510(k) for the Cirrus HD-OCT platform, expanding the capabilities of its anterior segment premier module to incl...

Human Drugs

Genentechs Tecentriq OKd for Breast Cancer

FDA grants Genentech accelerated approval for Tecentriq (atezolizumab) plus chemotherapy (Abraxane [paclitaxel protein-bound particles for injectable ...

Human Drugs

Sanofi sBLA for Dupixent in Treating Rhinosinusitis

FDA accepts for priority review a Sanofi supplemental BLA for Dupixent (dupilumab) as an add-on maintenance treatment for adults with inadequately con...

Human Drugs

Genentech sNDA Submitted for Venclexta for Leukemia

Genentech submits a supplemental NDA for Venclexta (venetoclax) in combination with Gazyva (obinutuzumab) in people with previously untreated chronic ...

Human Drugs

FDA Updates Biological Product Naming Guidance

FDA says it will no longer require that a suffix be added to the nonproprietary names of existing biological products.

Human Drugs

Foamix NDA Accepted for Acne Treatment

FDA accepts for review a Foamix Pharmaceuticals NDA for FMX101 (minocycline foam, 4%) for treating inflammatory lesions of non-nodular moderate-to-sev...

Federal Register

Panel to Discuss Testosterone Replacement Therapy Development

Federal Register notice: FDA announces a 4/8 Pediatric Advisory Committee meeting to discuss drug development for testosterone replacement therapy in ...

Medical Devices

Many Device Adverse Reports Hidden From Public: Report

A Kaiser Health News investigative report spotlights FDAs medical device adverse report alternative databases that are hidden from public view.

Medical Devices

MITA Raises Software Pre-Certification Issues

MITA raises four issues for FDA to consider for its software precertification program.